AHR and cancer: Currently, phase 1 clinical trials are ongoing for a novel AhR antagonist, BAY-2416964 (96), developed by Bayer and researchers at the German Cancer Research Center (DKFZ) for patients with advanced solid tumors (NCT04069026, NCT04999202).